Your browser doesn't support javascript.
loading
Hepatocyte-Secreted Autotaxin Exacerbates Nonalcoholic Fatty Liver Disease Through Autocrine Inhibition of the PPARα/FGF21 Axis.
Qiu, Han; Song, Erfei; Hu, Yue; Li, Tengfei; Ku, Kam Ching; Wang, Cunchuan; Cheung, Bernard M Y; Cheong, Lai Yee; Wang, Qin; Wu, Xiaoping; Hoo, Ruby L C; Wang, Yong; Xu, Aimin.
Afiliación
  • Qiu H; State Key Laboratory of Pharmaceutical Biotechnology, The University of Hong Kong, Hong Kong, China; Department of Medicine, The University of Hong Kong, Hong Kong, China.
  • Song E; State Key Laboratory of Pharmaceutical Biotechnology, The University of Hong Kong, Hong Kong, China; Department of Medicine, The University of Hong Kong, Hong Kong, China; Department of Metabolic and Bariatric Surgery, The First Affiliated Hospital of Jinan University, Guangzhou, China.
  • Hu Y; State Key Laboratory of Pharmaceutical Biotechnology, The University of Hong Kong, Hong Kong, China; Department of Medicine, The University of Hong Kong, Hong Kong, China.
  • Li T; State Key Laboratory of Pharmaceutical Biotechnology, The University of Hong Kong, Hong Kong, China; Department of Medicine, The University of Hong Kong, Hong Kong, China.
  • Ku KC; State Key Laboratory of Pharmaceutical Biotechnology, The University of Hong Kong, Hong Kong, China; Department of Medicine, The University of Hong Kong, Hong Kong, China.
  • Wang C; Department of Metabolic and Bariatric Surgery, The First Affiliated Hospital of Jinan University, Guangzhou, China.
  • Cheung BMY; State Key Laboratory of Pharmaceutical Biotechnology, The University of Hong Kong, Hong Kong, China; Department of Medicine, The University of Hong Kong, Hong Kong, China.
  • Cheong LY; State Key Laboratory of Pharmaceutical Biotechnology, The University of Hong Kong, Hong Kong, China; Department of Medicine, The University of Hong Kong, Hong Kong, China.
  • Wang Q; State Key Laboratory of Pharmaceutical Biotechnology, The University of Hong Kong, Hong Kong, China; Department of Medicine, The University of Hong Kong, Hong Kong, China.
  • Wu X; State Key Laboratory of Pharmaceutical Biotechnology, The University of Hong Kong, Hong Kong, China; Department of Pharmacology and Pharmacy, The University of Hong Kong, Hong Kong, China.
  • Hoo RLC; State Key Laboratory of Pharmaceutical Biotechnology, The University of Hong Kong, Hong Kong, China; Department of Pharmacology and Pharmacy, The University of Hong Kong, Hong Kong, China.
  • Wang Y; Department of General Surgery, The Second Hospital of Anhui Medical University, Hefei, China. Electronic address: wangyong@ahmu.edu.cn.
  • Xu A; State Key Laboratory of Pharmaceutical Biotechnology, The University of Hong Kong, Hong Kong, China; Department of Medicine, The University of Hong Kong, Hong Kong, China; Department of Pharmacology and Pharmacy, The University of Hong Kong, Hong Kong, China. Electronic address: amxu@hku.hk.
Cell Mol Gastroenterol Hepatol ; 14(5): 1003-1023, 2022.
Article en En | MEDLINE | ID: mdl-35931383
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Hidrolasas Diéster Fosfóricas / Enfermedad del Hígado Graso no Alcohólico Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Cell Mol Gastroenterol Hepatol Año: 2022 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Hidrolasas Diéster Fosfóricas / Enfermedad del Hígado Graso no Alcohólico Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Cell Mol Gastroenterol Hepatol Año: 2022 Tipo del documento: Article